[(4-甲基苯基)苯基甲基]哌嗪 | 68240-63-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: [(4-甲基苯基)苯基甲基]哌嗪
• 英文名称: 1-(p-Methylbenzhydryl)piperazine
• 英文别名: 1-(4-methyl-benzhydryl)-piperazine；1-[(4-methylphenyl)phenylmethyl]piperazine；[(4-Methylphenyl)phenylmethyl]piperazine；1-[(4-methylphenyl)-phenylmethyl]piperazine
• CAS: 68240-63-1
• 化学式: C₁₈H₂₂N₂
• 分子量: 266.386
• InChiKey: LRAIVZSSYJVWOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  [(4-甲基苯基)苯基甲基]哌嗪 在 氯甲酸乙酯 作用下， 生成 (E)-N-[4-[4-[(4-methylphenyl)-phenylmethyl]piperazin-1-yl]butyl]-3-(6-methylpyridin-3-yl)prop-2-enamide
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012
• 作为产物：
  描述：

  哌嗪 、 4-甲基二苯氯甲烷 在 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 生成 [(4-甲基苯基)苯基甲基]哌嗪
  参考文献：
  名称：

  Structure–activity relationships of diphenylpiperazine N-type calcium channel inhibitors

  摘要：

  A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.008

文献信息

• Pyrrolidine Carboxamides as a Novel Class of Inhibitors of Enoyl Acyl Carrier Protein Reductase from <i>Mycobacterium tuberculosis</i>
  作者：Xin He、Akram Alian、Robert Stroud、Paul R. Ortiz de Montellano

  DOI：10.1021/jm060715y

  日期：2006.10.1

  of Mycobacterium tuberculosis, there is an urgent need to discover antituberculosis agent with novel structures. InhA, the enoyl acyl carrier protein reductase (ENR) from M. tuberculosis, is one of the key enzymes involved in the mycobacterial fatty acid elongation cycle and has been validated as an effective antimicrobial target. We report here the discovery, through high-throughput screening, of

  鉴于结核分枝杆菌的多药耐药性在世界范围内的传播，迫切需要发现具有新颖结构的抗结核药。InhA是结核分枝杆菌的烯酰基酰基载体蛋白还原酶（ENR），是分枝杆菌脂肪酸延长周期中涉及的关键酶之一，已被证实是有效的抗菌靶标。我们在此报告通过高通量筛选发现的一系列吡咯烷羧酰胺，它们是一类新的强效InhA抑制剂。与三种抑制剂复合的InhA晶体结构已用于阐明抑制剂的结合模式。通过迭代微量滴定文库合成的后续优化，然后不经纯化就地进行活性筛选，可将先导化合物的效能提高160倍以上。
• Benzylpiperazine derivatives. IV. Syntheses and cerebral vasodilating activities of 1-benzyl-4-diphenylmethylpiperazine derivatives.
  作者：HIROSHI OHTAKA、TOSHIRO KANAZAWA、KEIZO ITO、GORO TSUKAMOTO

  DOI：10.1248/cpb.35.3270

  日期：——

  A series of 1-benzyl-4-diphenylmethylpiperazines was prepared and tested for cerebral vasodilating activity. Among the compounds with stronger potency and longer-lasting action than papaverine, the most potent analog 19 (KB-2796) was selected for further study. Some pharmacological properties of 19 are presented.

  一系列1-苄基-4-二苯甲基哌嗪化合物被制备并测试了其脑部血管舒张活性。在那些活性比罂粟碱更强且作用更持久的化合物中，最有效的类似物19（KB-2796）被选作进一步研究。本文展示了一些19的药理学特性。
• Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides
  作者：Xin He、Akram Alian、Paul R. Ortiz de Montellano

  DOI：10.1016/j.bmc.2007.08.013

  日期：2007.11

  drug-resistant clinical isolates. The crystal structure of InhA complexed with one representative inhibitor reveals the binding mode of the inhibitor within the InhA active site. Further optimization through a microtiter synthesis strategy followed by in situ activity screening led to the discovery of a potent InhA inhibitor with in vitro IC(50)=90 nM, representing a 34-fold potency improvement over the lead compound

  InhA是结核分枝杆菌的烯酰基酰基载体蛋白还原酶（ENR），是参与结核分枝杆菌II型脂肪酸生物合成途径的关键酶之一。我们在此报告通过高通量筛选发现的一系列芳基酰胺，它们是一类新型的有效InhA抑制剂。这些直接的InhA抑制剂不需要分枝杆菌的酶促活化作用，因此可以规避对耐药结核前药（如INH和ETA）的耐药机制，这种机制在耐药性临床分离株中最常见。与一种代表性抑制剂复合的InhA的晶体结构揭示了该抑制剂在InhA活性位点内的结合模式。
• [EN] PROCESS FOR THE PREPARATION OF ROSUVASTATIN<br/>[FR] PROCÉDÉ DE PRÉPARATION DE ROSUVASTATINE
  申请人：KRKA TOVARNA ZDRAVIL D D NOVO

  公开号：WO2010081861A1

  公开（公告）日：2010-07-22

  The invention relates to a process for the preparation of a HMG - CoA reductase inhibitor such as rosuvastatin, as well as intermediates useful in such process. The invention also relates to salts of HMG-CoA reductase inhibitors and processes for preparing same as well as processes for preparing pharmaceutically acceptable salts of HMG-CoA reductase inhibitors.

  该发明涉及一种用于制备类似罗伐他汀的HMG - CoA还原酶抑制剂的过程，以及在该过程中有用的中间体。该发明还涉及HMG-CoA还原酶抑制剂的盐以及制备其的过程，以及制备HMG-CoA还原酶抑制剂的药用可接受盐的过程。
• [EN] PROCESSES FOR PREPARATION OF MONTELUKAST SODIUM AND PURIFICATION OF DIOL INTERMEDIATE<br/>[FR] MÉTHODES DE PRÉPARATION DE MONTÉLUKAST DE SODIUM ET DE PURIFICATION D'UN INTERMÉDIAIRE DIOL
  申请人：IND SWIFT LAB LTD

  公开号：WO2012077133A1

  公开（公告）日：2012-06-14

  A process for preparation of montelukast sodium through novel montelukast amine salts is provided, wherein the amine is selected from 1- (l-naphthyl)ethylamine, S-methyl-L-cysteine, diallylamine or isomers thereof. A process for purification of 2-(2-(3-(S)-(3-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-hydroxylpropyl)-phenyl-2-propanol is also provided, which uses a halogenated hydrocarbon and a nitrile as solvent.

  提供一种通过新颖的蒙特鲁卡斯特胺盐制备蒙特鲁卡斯特钠的方法，其中所选的胺来自1-(1-萘基)乙胺，S-甲基-L-半胱氨酸，二烯基胺或其异构体。还提供了一种用卤代烃和腈作为溶剂的纯化2-(2-(3-(S)-(3-(7-氯-2-喹啉基)-乙烯基)苯基)-3-羟基丙基)-苯基-2-丙醇的方法。